MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - November 27, 2012) - MorphoSys AG /
MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of
Therapeutic Peptides. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys to Participate in Lanthio Pharma's Series A Financing
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today
collaboration with privately held Lanthio Pharma, a Dutch
company focused on discovering and developing lantipeptides.
comprise a novel class of therapeutics with high target selectivity and
drug-like properties. Lanthio Pharma's technology LanthioPep can be
identify peptides which are selective for a specific disease target
stabilize them in their optimal structural conformation for receptor
MorphoSys and Lanthio Pharma will jointly apply their respective
establish high quality and diverse lantipeptide-based libraries.
receives preferred rights to exclusively license the LanthioPep
MorphoSys will also make an equity investment in Lanthio Pharma as part
company's Series A financing round. After closure of the transaction,
will have a minority stake in Lanthio Pharma.
"Therapeutic peptides and especially so called stapled or constrained
comprise an emerging compound class which offers the potential to
multiple target classes and disease categories currently beyond
therapeutic proteins or small molecules. The combination of Lanthio
platform and our expertise in intelligent library design offers
opportunities for both companies and that's what got us excited,"
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"We are very pleased to have access to this novel technology
promising class of therapeutic peptides," commented Jens Holstein,
Financial Officer of MorphoSys. "This transaction represents a new
MorphoSys providing innovation capital to promising start-ups with
and product candidates being close to our core capabilities."
Lanthio Pharma applies its proprietary LanthioPep technology to discover
therapeutics with increased resistance to peptidase degradation, high
specificity and increased intrinsic activity. The high specificity can
new therapeutic applications around novel targets including
targets and GPCRs. Therapeutic plasma levels of lantipeptides can
achieved via oral, pulmonary or subcutaneous delivery. The technology
proprietary bacterial display capability, which allows for the
focused or diversified libraries of lanthionine-peptides. These libraries
for immediate functional screening and easy production of peptides of
for further in vivo and in vitro testing. Lanthio Pharma signed a
deal for its lead compound PanCyte, a lanthionine-stabilized
Angiotensin-(1-7) agonistic peptide for the treatment of pulmonary
US-based Tarix Pharmaceuticals, Inc. in 2012. The start of clinical
PanCyte is expected in 2013.
"Peptides are an attractive class of drugs, because they are used by the
itself to regulate physiological processes. A drawback of using
therapeutically can be their ability to interact with several
their rapid degradation by peptidases in the body. Lanthio Pharma's
can make peptides more receptor specific and the introduction of
also provides strong protection against peptidase degradation. As
lantipeptides typically have better "drug-like" properties, compared to
linear peptides. In combination with MorphoSys's outstanding
generating high-quality protein libraries we are confident that we can
lantipeptides to the next level," commented Bart Wuurman, CEO of Lanthio
About Lanthio Pharma:
Lanthio Pharma is a privately held drug discovery company that applies its
proprietary Lactococcus lactis based lanthionine-peptide drug discovery
(LanthioPep) technology to discover peptide therapeutics with increased
resistance to peptidase degradation, high receptor specificity and
Lanthio Pharma has generated stable, peptidase-resistant lanthionine
with highly specific agonistic activity for a number of GPCR targets, which
focus area of the company. Many peptide ligands are thought to bind to
GPCR receptors via a "turn motif", which can be stabilized in Lanthio
peptides with a strong thioether bond. Fixing the turn motif in its optimal
receptor binding conformation can result in potent and specific agonistic
The technology also includes a proprietary bacterial display library
which allows for the construction of focused or randomized libraries. These
libraries allow for immediate functional screening and easy production of
peptides of interest for further in-vivo and in-vitro testing.
Therapeutic products in Lanthio Pharma's pipeline include a
lanthionine-stabilized specific agonist of the AT2 receptor, which has
great potential in
diseases where tissue protection is important, like fibrosis.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
and Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE